Get the Stockscreener App
2.42
5.10%
-0.13
After Hours:
2.42
Achieve Life Sciences Inc stock is traded at $2.42, with a volume of 235.22K.
It is down -5.10% in the last 24 hours and down -15.09% over the past month.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
See More
Previous Close:
$2.55
Open:
$2.45
24h Volume:
235.22K
Relative Volume:
1.05
Market Cap:
$83.94M
Revenue:
-
Net Income/Loss:
$-32.94M
P/E Ratio:
-2.1802
EPS:
-1.11
Net Cash Flow:
$-24.95M
1W Performance:
-16.55%
1M Performance:
-15.09%
6M Performance:
-51.89%
1Y Performance:
-47.28%
1-Day Range:
$2.34
$2.53
1-Week Range:
$2.34
$2.89
52-Week Range:
$2.34
$5.59
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
2.42 | 83.94M | 0 | -32.94M | -24.95M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
Achieve Life Sciences Inc Stock (ACHV) Latest News
ACHV Stock Touches 52-Week Low at $2.5 Amid Market Challenges - Investing.com UK
ACHIEVE LIFE SCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Contrasting Achieve Life Sciences (NASDAQ:ACHV) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Achieve Life Sciences, Inc. (NASDAQ:ACHV) CFO Purchases $28,900.00 in Stock - MarketBeat
Insider Buying: Mark Oki Acquires Shares of Achieve Life Sciences Inc (ACHV) - GuruFocus
Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory - MSN
Achieve Life Sciences CEO Richard Stewart purchases $28,598 in stock - Investing.com India
Achieve Life Sciences CFO Mark Oki buys $28,887 in stock - Investing.com India
Achieve Life Sciences (ACHV) Expected to Announce Quarterly Earnings on Thursday - Defense World
Achieve Life Sciences Executives Acquire Shares - TradingView
Achieve Life Sciences CFO Mark Oki buys $28,887 in stock By Investing.com - Investing.com UK
Achieve Life Sciences CEO Richard Stewart purchases $28,598 in stock By Investing.com - Investing.com UK
Achieve Life Sciences: Promising Clinical Progress and Strategic Leadership Enhancements Justify Buy Rating - TipRanks
ACHV stock touches 52-week low at $2.81 amid market challenges - Investing.com India
Achieve Life Sciences (NASDAQ:ACHV) Announces Earnings Results - MarketBeat
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2024 Earnings Call Transcript - Insider Monkey
ACHV: 2Q:25 NDA Submission - Yahoo Finance
Achieve Life Sciences Inc (ACHV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo
Achieve Life Sciences Reports 2024 Financial Results - TipRanks
Achieve Life Sciences misses Q4 earnings, shares fall By Investing.com - Investing.com South Africa
Achieve Life Sciences misses Q4 earnings, shares fall - Investing.com
Earnings call transcript: Achieve Life Sciences Q4 2024 sees slight EPS miss By Investing.com - Investing.com South Africa
Earnings call transcript: Achieve Life Sciences Q4 2024 sees slight EPS miss - Investing.com
Achieve Life Sciences Q4 Loss Widens - Nasdaq
Achieve Life Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program - The Manila Times
ACHIEVE LIFE SCIENCES Earnings Results: $ACHV Reports Quarterly Earnings - Nasdaq
ACHIEVE LIFE SCIENCES, INC. SEC 10-K Report - TradingView
Achieve Life Sciences Announces Planned NDA Submission for Cytisinicline Targeting End of Q2 2025 - Nasdaq
Achieve Life Sciences Reports Financial Results for Fourth - GlobeNewswire
Achieve Life Sciences Hits Major FDA Milestone as Q4 Results Show $34.4M Cash Position - StockTitan
Earnings Scheduled For March 11, 2025 - Benzinga
SBI Securities Co. Ltd. Purchases New Shares in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Achieve Life Sciences (ACHV) Projected to Post Earnings on Tuesday - Defense World
Can This Smoking Cessation Drug Developer Disrupt a $20B Market? Key Presentation Coming - StockTitan
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference - The Manila Times
Achieve Life Sciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025 - The Manila Times
INVESTVIEW, INC. ANNOUNCES LAUNCH OF STOCK REPURCHASE PROGRAM - The Manila Times
Achieve Life Sciences to Report Fourth Quarter and Year-End 2024 Financial Results and Cytisinicline Development Update - Nasdaq
Achieve Life Sciences to Announce Fourth Quarter and - GlobeNewswire
Can This Smoking Cessation Drug Developer Turn 2024 Results Into 2025 Success? - Stock Titan
ACHV Stock Touches 52-Week Low at $2.83 Amid Market Challenges - Investing.com Australia
Qualia Supplements Achieve Multiple Finalist Honors For Product Excellence At 2025 NEXTY Awards - Yahoo Finance
ACHV Stock Touches 52-Week Low at $2.83 Amid Market Challenges By Investing.com - Investing.com South Africa
Achieve Life Sciences, Inc. to Host Earnings Call - ACCESS Newswire
Achieve Life Sciences to Participate in Two Upcoming Investor Conferences - ACCESS Newswire
Veradigm Becomes First EHR Media Platform to Achieve POCMA Certification - Business Wire
CBD Life Sciences Inc. (CBDL) Launches Mushroom Powder Capsules - ACCESS Newswire
Technology | Definition, Examples, Types, & Facts - Britannica
Artificial Intelligence (AI) in Life Sciences Market Size to Worth USD 13.89 Bn by 2034 - BioSpace
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):